Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP3 | O14638 | 5/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 4/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 4/20 | 0.38 |
| ▸ | GALR2 | O43603 | 2/20 | 0.36 |
| ▸ | GALR1 | P47211 | 2/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | IDH2 | P48735 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5042961 | 0.89 | HTR6 (0.45) | HTR6GALR2GALR1CCR6IDH2 | |
| SCHEMBL7148418 | 0.86 | GALR2 (0.47) | HTR6GALR2GALR1CCR6IDH2 | |
| SCHEMBL5033423 | 0.84 | ENPP3 (0.40) | ENPP3ENPP1ENPP2HTR6 | |
| SCHEMBL5033414 | 0.84 | MAPT (0.41) | HTR6IDH2SYK | |
| SCHEMBL5037857 | 0.82 | ENPP3 (0.40) | ENPP3ENPP1ENPP2HTR6CCR6 | |
| SCHEMBL5033442 | 0.81 | NPC1 (0.38) | ENPP3ENPP1ENPP2HTR6SYK | |
| SCHEMBL5043065 | 0.80 | NPC1 (0.44) | ENPP3ENPP1ENPP2KDRHTR6 | |
| SCHEMBL5033699 | 0.78 | NPC1 (0.46) | KDRGALR2GALR1 | |
| SCHEMBL5037881 | 0.77 | LMNA (0.43) | JAK2JAK1JAK3SYK | |
| SCHEMBL5036539 | 0.77 | ENPP3 (0.50) | ENPP3ENPP1ENPP2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | claimed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | claimed |
| EP-1432417-B1 | SUBSTITUTED BENZIMIDAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF CANCER | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | EP | disclosed |
| US-7041668-B2 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2006-05-09 | — | — | US | disclosed |
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | AVENTIS PHARMA S.A. (FR) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014811-A1 | Substituted benzimidazole compounds and their use for the treatment of cancer | CDKL3, CCNL2, CDKL1 | ENPP3 2927/4885ENPP1 3915/4885ENPP2 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.